Neuralink, Elon Musk's brain-computer interface company, is commanding valuations of up to $42 billion in private stock trading, according to Business Insider on the 22nd local time. Recent share transactions are occurring at enterprise values ranging from $29 billion to $42 billion, with some investors attempting purchases at approximately $60 billion valuations. The surge reflects intensified investor demand for Musk-led artificial intelligence and robotics ventures following SpaceX's recent successful initial public offering, with Neuralink's current valuation representing roughly five times the $9 billion enterprise value recognized during last year's funding round.
Neuralink Valuation Surges to $42 Billion in Private Trading
Neuralink's private share transactions are currently occurring at enterprise values between $29 billion and $42 billion, with some investors bidding at approximately $60 billion, Business Insider reported on the 22nd local time. This valuation range marks a significant increase from the $9 billion enterprise value the company received during last year's investment round. Market analysts attribute the valuation surge to heightened investor interest in Musk's artificial intelligence and robotics businesses. SpaceX's recent successful IPO has further amplified attention toward Musk's other private companies, with SpaceX's current market capitalization reaching approximately $1.6 trillion.
Investor Demand Drives Secondary Market Activity
As a private company, Neuralink shares trade through secondary markets where employees and early investors transact their holdings. The enterprise values currently discussed represent market demand estimates rather than official company valuations. One venture capital investor stated that multiple institutional investors "want to purchase Neuralink shares regardless of price." However, market observers note that current trading prices may be excessively high, with opinions on Neuralink's appropriate enterprise value remaining divided.
Clinical Trial Status and Technology Development
Neuralink is developing brain-implantable chips enabling paralyzed patients to control computers through thought. The company's long-term objectives include developing vision restoration technology. Technology development remains in early stages—the company disclosed that as of early this year, chips had been implanted in a total of 21 clinical trial participants. Musk's personal wealth increased substantially following SpaceX's IPO last month.
FAQ
What valuation is Neuralink achieving in private stock trading?
Neuralink's private shares are trading at enterprise values ranging from $29 billion to $42 billion, with some investors bidding at approximately $60 billion, according to Business Insider on the 22nd local time. This represents roughly five times the $9 billion valuation from last year's funding round.
How many clinical trial participants has Neuralink enrolled?
Neuralink disclosed that as of early this year, the company had implanted its brain-computer interface chips in a total of 21 clinical trial participants. The technology enables paralyzed patients to control computers through thought, though development remains in early stages.
